|
Video: What is a Stock Split?
|
|
BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza. According to our BioCryst Pharmaceuticals stock split history records, BioCryst Pharmaceuticals has had 0 splits. | |
|
BioCryst Pharmaceuticals (BCRX) has 0 splits in our BioCryst Pharmaceuticals stock split history database.
Looking at the BioCryst Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into BioCryst Pharmaceuticals shares, starting with a $10,000 purchase of BCRX, presented on a split-history-adjusted basis factoring in the complete BioCryst Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$10.90 |
|
End price/share: |
$5.08 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-53.39% |
|
Average Annual Total Return: |
-7.35% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$4,661.71 |
|
Years: |
10.00 |
|
|
|
|
|